Palvella Therapeutics (PVLA) Interest & Investment Income (2015 - 2024)
Palvella Therapeutics (PVLA) reported Interest & Investment Income of $169000.0 for Q3 2024, down 69.22% year-over-year from $549000.0 in Q4 2023, and down 15.92% on a QoQ basis from $201000.0 in Q2 2024.
Palvella Therapeutics (PVLA) has 9 years of Interest & Investment Income data on file, last reported at $169000.0 in Q3 2024.
- Quarterly Interest & Investment Income fell 69.22% year-over-year to $169000.0 in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $1.2 million (down 29.2% YoY) and the FY2021 annual result came in at $4000.0, down 99.22% from the prior year.
- Interest & Investment Income retreated to $169000.0 in Q3 2024 per PVLA's latest filing, from $201000.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $549000.0 in Q3 2023 and bottomed at -$6000.0 in Q4 2021.
- The 5-year median for Interest & Investment Income is $132000.0 (2022), against an average of $170058.8.
- The widest annual swing landed in 2022, when Interest & Investment Income slumped 200.0%; it then surged 12000.0% in 2023.
- Tracing PVLA's Interest & Investment Income over 5 years: stood at $8000.0 in 2020, then slumped by 175.0% to -$6000.0 in 2021, then jumped by 4116.67% to $241000.0 in 2022, then surged by 127.8% to $549000.0 in 2023, then plunged by 69.22% to $169000.0 in 2024.
- Per Business Quant, the three latest PVLA Interest & Investment Income figures stand at $169000.0 (Q3 2024), $201000.0 (Q2 2024), and $240000.0 (Q1 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 7.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 114.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 305,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 26.60 Mn |
| 10 | Palvella Therapeutics | 1.47 Bn | 1.21 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 169,000.00 |
| Jun 30, 2024 | 201,000.00 |
| Mar 31, 2024 | 240,000.00 |
| Sep 30, 2023 | 549,000.00 |
| Jun 30, 2023 | 490,000.00 |
| Mar 31, 2023 | 357,000.00 |
| Sep 30, 2022 | 241,000.00 |
| Jun 30, 2022 | 132,000.00 |
| Mar 31, 2022 | -3,000.00 |
| Dec 31, 2021 | -6,000.00 |
| Sep 30, 2021 | 4,000.00 |
| Jun 30, 2021 | 3,000.00 |
| Mar 31, 2021 | 3,000.00 |
| Dec 31, 2020 | 8,000.00 |
| Sep 30, 2020 | 55,000.00 |
| Jun 30, 2020 | 129,000.00 |
| Mar 31, 2020 | 319,000.00 |
| Dec 31, 2019 | 382,000.00 |
| Sep 30, 2019 | 377,000.00 |
| Jun 30, 2019 | 449,000.00 |
| Mar 31, 2019 | 506,000.00 |
| Dec 31, 2018 | 471,000.00 |
| Sep 30, 2018 | 504,000.00 |
| Jun 30, 2018 | 662,000.00 |
| Mar 31, 2018 | 325,000.00 |
| Dec 31, 2017 | 152,000.00 |
| Dec 31, 2015 | -180,422.00 |
| Jun 30, 2015 | -53.00 |
| Mar 31, 2015 | -4,170.00 |